Tin tức & Cập nhật
Xem bài viết Da liễu
Xem
Chỉ hiển thị Multimedia

Dupilumab trumps MTX, cyclosporine in paediatric AD
03 Feb 2025
bởiStephen Padilla
The use of dupilumab in children with moderate-to-severe atopic dermatitis (AD) results in greater improvements in AD severity, better adherence, and fewer treatment-emergent adverse events (TEAEs) than methotrexate (MTX) or cyclosporine, as shown by 2-year interim results from the PEDISTAD study.
03 Feb 2025

Dupilumab-associated ocular surface disease less common in children, teens with AD
18 Jan 2025
bởiMike Ng
The incidence of ocular surface disease associated with dupilumab treatment for moderate-to-severe atopic dermatitis is lower in children and adolescents than that described in adults, suggests a retrospective review at a tertiary paediatric hospital in Singapore
18 Jan 2025






